These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37051241)

  • 1. Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab.
    Lin YT; Li CF; Wu HC; Jan YH; Kuo YH
    Front Immunol; 2023; 14():1131448. PubMed ID: 37051241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement.
    Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
    Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.
    Wang A; Jin Y; Cao Z; Lu L; Li Z
    Cancer Med; 2024 Jan; 13(1):e6809. PubMed ID: 38124509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.
    Iijima Y; Sakakibara R; Ishizuka M; Honda T; Shirai T; Okamoto T; Tateishi T; Sakashita H; Tamaoka M; Takemoto A; Kumaki Y; Ikeda S; Miyazaki Y
    Immunotherapy; 2020 Jun; 12(8):563-569. PubMed ID: 32363992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked Response to Nivolumab by a Patient With SMARCA4-Deficient Undifferentiated Urothelial Carcinoma Showing High PD-L1 Expression: A Case Report.
    Arihara Y; Omori G; Kobayashi K; Sugita S; Murase K; Kubo T; Idogawa M; Hasegawa T; Takada K
    Cancer Rep (Hoboken); 2024 Jun; 7(6):e2127. PubMed ID: 38923369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    PeerJ; 2024; 12():e16923. PubMed ID: 38374950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
    Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression.
    Mao R; Liu M; Shu X; Li W; Yan W; Li X
    Int J Surg Pathol; 2022 May; 30(3):251-259. PubMed ID: 34633874
    [No Abstract]   [Full Text] [Related]  

  • 12. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.
    Panozzi M; Alì G; Proietti A; Melfi F; Zirafa CC; Lucchi M; Fontanini G
    Pathologica; 2023 Jun; 115(3):164-171. PubMed ID: 37387441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
    Chatzopoulos K; Boland JM
    Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
    Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features.
    Sun T; Gilani SM; Podany P; Harigopal M; Zhong M; Wang H
    Cancer Cytopathol; 2022 Aug; 130(8):620-629. PubMed ID: 35468657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
    Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
    Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
    Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
    Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report.
    Minoshima A; Sugita S; Segawa K; Aoyama T; Ito M; Daimon F; Takenami T; Kido T; Moriya J; Nishikiori H; Hasegawa T
    Diagn Cytopathol; 2023 May; 51(5):E149-E154. PubMed ID: 36772934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.